New Phase 3 Clinical Trial Opens for Pediatric, Adult Hodgkin Lymphoma Patients

While an estimated 95% of “younger” patients diagnosed with Hodgkin lymphoma are still alive and into survivorship within five years of their diagnosis, their long-term health suffers from the aggressive treatment needed to fight the disease.

November 10, 2025

Roswell Park Comprehensive Cancer Center

Objective:

To evaluate the efficacy of immunotherapy in reducing treatment intensity and long-term complications in patients with stage 1 or 2 Hodgkin lymphoma, aiming to improve overall survival rates.

Approach:

Key Findings:

95% of younger Hodgkin lymphoma patients survive 5 years but face long-term health complications, necessitating improved treatment strategies.
Immunotherapy may reduce the need for conventional chemotherapy and radiation, which contribute to long-term toxicity, potentially leading to better quality of life.
The trial anticipates only 15% of patients will require radiation, a significant reduction from historical rates, indicating a shift in treatment paradigms.

Interpretation:

Incorporating immunotherapy could lead to improved long-term survival rates and reduced treatment-related complications in Hodgkin lymphoma patients, enhancing their quality of life.

Limitations:

Exclusion of patients with a history of autoimmune disease from the trial may limit the generalizability of the results.
Potential variability in patient responses to immunotherapy could affect the overall efficacy and safety profile of the treatment.

Conclusion:

The AHOD2131 trial represents a significant advancement in Hodgkin lymphoma treatment, aiming to enhance survivorship while minimizing long-term health risks.